Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
From MaRDI portal
(Redirected from Publication:87467)
Recommendations
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
- The validation of surrogate endpoints in meta-analyses of randomized experiments
- The evaluation of surrogate endpoints.
- Validation of surrogate markers in multiple randomized clinical trials with repeated measurements
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
Cited in
(52)- Bayesian ridge estimators based on copula-based joint prior distributions for regression coefficients
- Bivariate network meta-analysis for surrogate endpoint evaluation
- One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints
- Optimizing and evaluating biomarker combinations as trial-level general surrogates
- Quantifying the association between progression-free survival and overall survival in oncology trials using Kendall's \(\tau\)
- Multi-stage enrichment and basket trial designs with population selection
- Estimation of treatment effect in 2-in-1 adaptive design and some of its extensions
- Choice of units of analysis and modeling strategies in multilevel hierarchical models
- The evaluation of surrogate endpoints.
- Validation of surrogate markers in multiple randomized clinical trials with repeated measurements
- Confirmatory adaptive group sequential designs for single‐arm phase II studies with multiple time‐to‐event endpoints
- Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling
- Multivariate frailty models for two types of recurrent events with a dependent terminal event: application to breast cancer data
- Meta-analysis of individual patient data with semi-competing risks under the Weibull joint frailty-copula model
- Unbalanced cluster sizes and rates of convergence in mixed-effects models for clustered data
- Generalized shared-parameter models and missingness at random
- Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements: Canonical Correlation Approach
- Pairwise Fitting of Mixed Models for the Joint Modeling of Multivariate Longitudinal Profiles
- Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials
- Dynamic lifetime prediction using a Weibull-based bivariate failure time model: a meta-analysis of individual-patient data
- Exploring and validating surrogate endpoints in colorectal cancer
- Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling
- Confidence intervals and statistical power of the ``Validation ratio for surrogate or intermediate endpoints
- The Evaluation of Multiple Surrogate Endpoints
- Using surrogate failure time data to increase cost effectiveness in clinical trials
- Center-within-trial versus trial-level evaluation of surrogate endpoints
- An information-theoretic approach to surrogate-marker evaluation with failure time endpoints
- Bayesian adaptive trial design for a newly validated surrogate endpoint
- Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes
- On composite marginal likelihoods
- surrosurv
- Missing data methods in longitudinal studies: a review
- Validation of a longitudinally measured surrogate marker for a time-to-event endpoint
- Semiparametric Inference for Surrogate Endpoints with Bivariate Censored Data
- True endpoint reduction by surrogate endpoints
- Simplified modeling strategies for surrogate validation with multivariate failure-time data
- Estimation of a common mean vector in bivariate meta-analysis under the FGM copula
- Cluster-robust estimators for multivariate mixed-effects meta-regression
- On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm
- The validation of surrogate endpoints in meta-analyses of randomized experiments
- Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials
- Testing for Heterogeneity in the Utility of a Surrogate Marker
- Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
- A perspective on surrogate endpoints in controlled clinical trials
- Assessing the numerical integration of dynamic prediction formulas using the exact expressions under the joint frailty-copula model
- The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
- A joint frailty‐copula model for meta‐analytic validation of failure time surrogate endpoints in clinical trials
- Joint modeling of progression-free and overall survival and computation of correlation measures
- Incomplete multiresponse designs and surrogate endpoints in clinical trials
- Bayesian ridge regression for survival data based on a vine copula-based prior
- Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
- Assessing the value of a censored surrogate outcome
This page was built for publication: Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q87467)
